v
Search
Advanced

Publications > Journals > Latest Articles

Results per page:
v
Review Article Open Access
Hao Li, Xianglin Meng
Published online September 30, 2026
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00002
Abstract
Despite the 2012 Berlin definition standardizing acute respiratory distress syndrome (ARDS) diagnosis, pharmacological therapies have consistently failed in phase 3 trials, partly [...] Read more.

Despite the 2012 Berlin definition standardizing acute respiratory distress syndrome (ARDS) diagnosis, pharmacological therapies have consistently failed in phase 3 trials, partly reflecting the syndrome’s profound biological heterogeneity. We synthesize evidence on ARDS subphenotyping to evaluate prospects for precision medicine. This narrative review was informed by targeted searches of PubMed/MEDLINE, Embase, and Web of Science from database inception through February 2026, supplemented by an updated PubMed/MEDLINE search through September 2026. Representative clinical trials, multicenter cohorts, mechanistic studies, and methodological reports were selected to support a critical synthesis of ARDS subphenotyping, its therapeutic implications, and barriers to clinical translation. Hyperinflammatory and hypoinflammatory subphenotypes—originally identified using plasma biomarkers (IL-6, IL-8, and soluble tumor necrosis factor receptor 1) in the ARMA and ALVEOLI cohorts—demonstrate reproducible differences in mortality, with worse outcomes in the hyperinflammatory subphenotype, and have shown potential treatment-effect heterogeneity in secondary analyses. Approximately 30%–35% of patients exhibit the hyperinflammatory profile, characterized by greater vasopressor requirements and organ failure. Radiological phenotypes (focal versus non-focal) on computed tomography imaging have been associated with differences in lung recruitability and physiological responses to ventilatory interventions, although the LIVE trial did not demonstrate an overall survival benefit from morphology-guided ventilation. Recent multi-omics studies (transcriptomic, proteomic, and metabolomic) reveal distinct endotypes involving dysregulated innate immunity, endothelial activation, and aberrant coagulation. Machine learning algorithms, particularly unsupervised clustering and deep learning-based computed tomography radiomics, have been investigated for more rapid phenotyping, but reported performance varies by task, cohort, and validation design. However, prospective, phenotype-guided randomized trials remain limited. Subphenotype stratification offers a mechanistically grounded framework for re-evaluating therapies that were ineffective in unselected populations and for investigating phenotype-informed ventilatory strategies. Clinical implementation requires standardized, bedside-compatible biomarker panels and definitive trials demonstrating that phenotype-specific interventions improve patient-centered outcomes.

Full article
Review Article Open Access
Gerd Klinkmann, Claudio Ronco, on behalf of the Studies Utilizing Blood Purification in Limiting the Overdose in Treatments (SUBPLOT) Investigators
Published online September 30, 2026
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00004S
Abstract
Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent [...] Read more.

Extracorporeal treatment (ECTR) is used in selected severe poisonings to enhance toxin elimination and, in some cases, provide temporary organ support. Modalities include intermittent hemodialysis, continuous renal replacement therapy, and sorbent-based hemoperfusion or hemoadsorption, each with distinct mechanisms and toxicokinetic implications. This narrative review summarizes modality-specific and toxin-specific evidence, operational treatment characteristics, patient-centered and toxicokinetic outcomes, safety considerations, and scenarios in which ECTR should be withheld, and proposes a practical five-step bedside algorithm. Sources were identified through targeted searches of PubMed/MEDLINE and Google Scholar, supplemented by Extracorporeal Treatments in Poisoning (EXTRIP) consensus documents, reference-list screening, and author expertise. The evidence base varies substantially across toxins. For several pharmaceutical poisonings, EXTRIP provides the most actionable guidance on indications, preferred modality, and stopping criteria, while recommending against ECTR for digoxin and methotrexate. Outside these consensus-guided settings, the largest experience with sorbent therapies concerns paraquat and organophosphorus/carbamate poisoning, although the literature is regionally concentrated and predominantly observational. In paraquat poisoning, hemoadsorption-containing strategies have been associated with improved survival in observational cohorts, while pharmacokinetic studies support early and repeated treatment in selected patients because of ongoing toxin removal and post-treatment rebound. In organophosphorus/carbamate poisoning, comparative studies suggest possible benefit in severe presentations, but certainty remains low. In diquat poisoning, recent reports emphasize concentration-directed extracorporeal strategies. Evidence for other toxins is largely limited to feasibility, toxin removal, and case-based experience. ECTR should therefore be regarded as a toxin-specific therapeutic toolbox rather than a uniform intervention. Where available, EXTRIP recommendations should guide practice. Otherwise, modality selection should integrate toxicokinetic plausibility, clinical severity, feasibility, and safety. Prospective studies using standardized prescriptions and clinically meaningful endpoints are needed.

Full article
Original Article Open Access
Gianmarco Adinolfi, Valeria Milia
Published online September 29, 2026
Cancer Screening and Prevention. doi:10.14218/CSP.2026.00015
Abstract
Artificial intelligence (AI)-based computer-aided detection (CADe) has been associated with improved adenoma detection during colonoscopy. However, prior meta-analyses synthesized [...] Read more.

Artificial intelligence (AI)-based computer-aided detection (CADe) has been associated with improved adenoma detection during colonoscopy. However, prior meta-analyses synthesized earlier trials, and whether the benefit remains consistent in recent contemporary trials is uncertain. This meta-analysis aimed to estimate the effects of current-generation AI-assisted colonoscopy on adenoma detection rate (ADR) as the primary outcome and polyp detection rate (PDR) as the secondary outcome in randomized and quasi-randomized trials published from August 1, 2024, to August 18, 2026, without re-pooling trials included in earlier comprehensive meta-analyses.

MEDLINE/PubMed, Embase, CENTRAL, Scopus, and Google Scholar were searched for peer-reviewed parallel-group randomized and quasi-randomized trials enrolling adults undergoing screening, surveillance, or diagnostic colonoscopy and comparing real-time AI-based CADe-assisted with conventional high-definition white-light colonoscopy. Tandem designs were excluded. The primary and secondary outcomes were ADR and PDR, respectively. Random-effects risk ratios with 95% confidence intervals (CIs) were calculated; heterogeneity and leave-one-out sensitivity were assessed.

Seventeen trials comprising 15,242 patients were included for ADR; 12 trials comprising 8,665 patients reported extractable PDR data. The pooled risk ratio was 1.14 (95% CI 1.09–1.20; I² = 53.8%) for ADR and 1.13 (95% CI 1.07–1.20; I² = 63.4%) for PDR.

This meta-analysis supports an average improvement in adenoma and polyp detection with AI-assisted colonoscopy; however, moderate-to-substantial heterogeneity and variability across settings and platforms warrant cautious interpretation rather than an unqualified recommendation for routine adoption.

Full article
Research Letter Open Access
Sadaf Barakzoy, Elie Farha, Alexandre Sayadi, Mylène Sebagh, Eric Vibert, Marc Antoine Allard
Published online September 29, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00399
Illuminating and Instructive Clinical Case Open Access
Fei Liu, Xiaoqing Fu, Haiyan Yu, Chuntao Liu, Shourong Liu, Rui Wu
Published online September 29, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00167
Abstract
Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with lymphoma receiving immunosuppressive therapy, particularly rituximab-containing regimens. [...] Read more.

Hepatitis B virus (HBV) reactivation is a well-recognized complication in patients with lymphoma receiving immunosuppressive therapy, particularly rituximab-containing regimens. We describe a 58-year-old man with diffuse large B-cell lymphoma and an atypical baseline HBV serological profile: hepatitis B surface antibody (anti-HBs) positivity (102.00 U/L), antibody to hepatitis B core antigen negativity, a low-level hepatitis B surface antigen (HBsAg) result (0.35 COI, reported as negative by the local laboratory), and undetectable HBV DNA. Thirteen days after initiation of the fourth cycle of modified R-CHOP (rituximab, cyclophosphamide, pirarubicin, vinorelbine and dexamethasone) chemoimmunotherapy, the anti-HBs titer had decreased to 1.31 S/CO, the HBsAg level to 0.02 S/CO, and HBV DNA was not reassessed until reactivation. Approximately 16 weeks after treatment completion, the patient developed fatigue, anorexia, and jaundice. HBsAg increased from 28.66 S/CO to 8,048.30 IU/mL, hepatitis B e antigen became positive, and HBV DNA increased to 1.94 × 109 IU/mL. Despite treatment with tenofovir alafenamide fumarate and plasma exchange, the patient died of refractory liver failure and hepatic encephalopathy. These findings suggest that atypical serological profiles may not reliably indicate a low risk of severe HBV reactivation during intensive immunosuppressive therapy. Comprehensive pretreatment risk assessment and long-term monitoring of anti-HBs titers, HBsAg, and HBV DNA during and after therapy may facilitate earlier detection and intervention.

Full article
Original Article Open Access
Zhao Li, Yuhua Chen, Yulan Zhu, Zhiwei Chen, Peng Hu
Published online September 29, 2026
Journal of Clinical and Translational Hepatology. doi:10.14218/JCTH.2026.00708
Abstract
Viral hepatitis caused by A to E imposes a substantial global burden of liver disease. Despite US control strategies, long-term national data covering serologic markers of all five [...] Read more.

Viral hepatitis caused by A to E imposes a substantial global burden of liver disease. Despite US control strategies, long-term national data covering serologic markers of all five hepatitis viruses remain limited. In this study, we analyzed epidemiologic trends from 2011 to 2023 and aimed to identify prevention gaps.

We analyzed National Health and Nutrition Examination Survey (NHANES) data from 2011 to 2023 using weighted logistic regression, with stratification by age, sex, and race/ethnicity.

Current hepatitis B virus (HBV) infection remained stable at 0.3%, while HBV susceptibility was 71.3%. Among individuals born in 1991 or later, HBV vaccination coverage declined from 90.0% to 83.6% during 2011–2020 (P for trend = 0.012); 57.0% of participants reporting vaccination were serologically susceptible. Anti-HDV positivity among participants with current HBV infection was 1.3%. Anti-hepatitis C virus (HCV) seroprevalence remained 1.6%, while active HCV viremia decreased from 0.8% to 0.4%, and viremia among anti-HCV-positive participants fell from 65.5% to 31.3% (P = 0.004). Hepatitis A virus antibody seroprevalence increased from 41.6% to 48.0% (P < 0.001) with stable vaccination coverage. Anti-HEV IgM positivity increased from 1.6% to 1.7% (P = 0.004).

US viral hepatitis trends diverged from 2011 to 2023. The decrease in detectable HCV RNA was consistent with progress in HCV control, whereas persistent HBV susceptibility, declining vaccination coverage in younger birth cohorts, and increasing hepatitis A virus seroprevalence and hepatitis E virus IgM positivity indicate ongoing prevention and surveillance needs.

Full article
Mini Review Open Access
Peng-Yu Zhao, Ming-Zhu Jin, Wei-Lin Jin
Published online September 29, 2026
Oncology Advances. doi:10.14218/OnA.2026.00015
Abstract
Interactions among tumors, nerves, and immune cells influence cancer progression, but the mechanisms coordinating these compartments remain incompletely understood. Bioelectric [...] Read more.

Interactions among tumors, nerves, and immune cells influence cancer progression, but the mechanisms coordinating these compartments remain incompletely understood. Bioelectric signaling has been proposed as an additional coordinating layer, yet direct in vivo evidence for a tumor–nerve–immune electrical axis remains limited. In non-tumor models, RUSH3D-HR enables mesoscale in vivo imaging of dynamic cellular behaviors, including neutrophil swarming and migrasome dynamics, and has revealed reduced splenic neutrophil swarming following electroacupuncture at Zusanli (ST36). These observations provide dynamic cellular readouts and demonstrate an intervention-associated response; however, the platform does not directly measure membrane voltage, ionic currents, or electric fields, and these findings establish neither electrical coupling nor a specific neural circuit. In this mini review, we examine the proposed axis as a focused, falsifiable complement to broader cancer neuroscience. We distinguish direct observations from mechanistic hypotheses, consider established biochemical explanations involving neurotransmitters and inflammatory mediators, and discuss how context-dependent neural effects, supporting glial cells, opioids, and cancer-induced nerve injury may modify tumor–nerve–immune interactions. We then outline a staged experimental roadmap in tumor models, integrating RUSH3D-HR with voltage and ion reporters, extracellular electrophysiological recordings, and compartment-specific perturbations. This framework prioritizes temporal relationships, identification of candidate signal sources and responding compartments, and causal tests that discriminate electrical contributions from biochemical and systemic effects. Establishing reproducible links between electrical measurements, cellular behavior, and tumor outcomes will be essential for evaluating the axis. Until such evidence is obtained, the tumor–nerve–immune electrical axis should be regarded as a hypothesis-generating experimental program rather than a validated physiological circuit.

Full article
Review Article Open Access
Shengnan Kong, Lin Chen, Haojia Lyu, Qin Lai, Xinya Li, Yu Wang, Jun Lyu
Published online September 28, 2026
Journal of Translational Critical Care Medicine. doi:10.14218/JTCCM.2026.00011
Abstract
Large-scale critical care databases have expanded opportunities for clinical research. Previous reviews have summarized open-access intensive care unit databases and specific analytical [...] Read more.

Large-scale critical care databases have expanded opportunities for clinical research. Previous reviews have summarized open-access intensive care unit databases and specific analytical methods, but integrated, practice-oriented guidance on commonly used and emerging methods and their selection remains limited. The objective of this narrative review is to provide a practice-oriented overview of commonly used and emerging statistical and modeling methods in critical care database research, with emphasis on their appropriate applications, strengths, limitations, and considerations for method selection. This narrative review summarizes commonly used and emerging methods in critical care database research, focusing on their applications, strengths, limitations, and practical considerations. The methods reviewed range from descriptive and regression analyses to prediction modeling, longitudinal analysis, causal inference, and artificial intelligence-based approaches. Common problems include missing data, temporal bias, confounding, overfitting, and limited external validation. Careful method selection and appropriate validation are therefore important when working with complex critical care data. Closer coordination of clinical questions, data structures, analytical methods, and reporting standards can strengthen research using intensive care unit databases. Paying closer attention to data quality, causal hypotheses, validation, reproducibility, and generalizability may improve the methodological rigor and translational value of these studies.

Full article
Original Article Open Access
Yan Ouyang, Yanjun Luo, Yuxin Zhan, Min Liu, Qi Li, Wenjing Li, Lianlian Qu, Suyun Li
Published online September 28, 2026
Neurosurgical Subspecialties. doi:10.14218/NSSS.2026.00013
Abstract
Therapeutic hypothermia (TH) is widely used as a neuroprotective strategy, but variability in bedside implementation may limit its optimal application. This study aimed to develop [...] Read more.

Therapeutic hypothermia (TH) is widely used as a neuroprotective strategy, but variability in bedside implementation may limit its optimal application. This study aimed to develop a standardized TH management protocol for patients with neurocritical illness and evaluate the clinical outcomes associated with its implementation.

An evidence-based TH protocol was developed through a two-round Delphi consensus process. A subsequent observational before-and-after study included 244 patients with neurocritical illness receiving TH. The historical control group (n = 120) received routine care, whereas the TH protocol group (n = 124) was managed according to the standardized protocol. No single primary endpoint was prespecified for the final comparative analysis. Outcomes were interpreted as exploratory and included temperature-management process indicators, individual TH-related complications requiring intervention, and neurological outcomes assessed using the Glasgow Outcome Scale.

Protocol implementation was associated with more favorable temperature-management process indicators, including earlier TH initiation, a shorter recorded time to target temperature, fewer unplanned treatment interruptions, a longer controlled rewarming phase, and greater adherence to rewarming criteria. In exploratory analyses, the TH protocol group had lower incidences of selected TH-related complications and more favorable Glasgow Outcome Scale outcomes at discharge than the historical control group.

Implementation of a consensus-derived TH management protocol was associated with more consistent temperature-management processes, fewer selected TH-related complications, and more favorable short-term neurological outcomes. These findings support prospective evaluation of protocolized TH management in larger multicenter cohorts.

Full article
Editorial Open Access
PrevPage 5 of 10 12…456…910Next
Back to Top